Inclusion Criteria:

- Patients with Philadelphia chromosome positive, chronic, accelerated or blast phase
BML or ALL.

- Patients must have primary or acquired hematologic resistance to imatinib mesylate or
have intolerance of imatinib mesylate.

- Men and women, 14 years of age or older.

- Adequate renal function.

- Adequate hepatic function.

- Women of childbearing potential (WOCBP) must be using an adequate method of
contraception to avoid pregnancy throughout the study and for a period of at least 1
month before and at least 3 months after the study in such a manner that the risk of
pregnancy is minimized.

Exclusion Criteria:

- Patients who are eligible and willing to undergo transplantation during the screening
period.

- Women who are pregnant or breastfeeding.

- A serious uncontrolled medical disorder or active infection that would impair the
ability of the subject to receive protocol therapy.

- Uncontrolled or significant cardiovascular disease.

- Medications that increase bleeding risk.

- Medications that change heart rhythms.

- Dementia or altered mental status that would prohibit the understanding of rendering
of informed consent.

- History of significant bleeding disorder or unrelated to CML.

- Evidence of organ dysfunction or digestive dysfunction that would prevent
administration of study therapy.

- Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for
treatment of either a psychiatric or physical (e.g., infectious disease) illness must
not be enrolled into this study.